STOCK TITAN

Revolution Medicines advisor sells 27,160 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Stephen Michael Kelsey, a Senior Advisor to the Chief Executive Officer, exercised options for 27,160 Revolution Medicines, Inc. shares on November 16, 2026, at an exercise price of $18.56 per share. He sold 27,160 shares that day in six transactions, at reported weighted-average prices of $166.7506, $167.6619, $168.6375, $169.4561, $170.3957 and $171.6500 per share.

Insider Kelsey Stephen Michael
Role See Remarks
Sold 27,160 shs ($4.56M)
Approx. gross sale proceeds $4.56M
Approx. exercise cost $504K
Approx. pre-tax spread $4.06M
Share of Position Sold 8.7%
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F8 27,160 $0.00 $0.00
Exercise Common Stock F1 27,160 $18.56 $504K
Sale Common Stock F1, F2 11,542 $166.7506 $1.92M
Sale Common Stock F1, F3 3,627 $167.6619 $608K
Sale Common Stock F1, F4 8,039 $168.6375 $1.36M
Sale Common Stock F1, F5 3,052 $169.4561 $517K
Sale Common Stock F1, F6 700 $170.3957 $119K
Sale Common Stock F1, F7 200 $171.65 $34K
Holdings After Transaction: Stock Option (Right to Buy) — 108,640 options (Direct); Common Stock — 286,307 shares (Direct)
Holdings Before and After: Stock Option (Right to Buy), 135,800 to 108,640 options (Direct); Common Stock, 286,307 to 286,307 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (8)
  1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on August 17, 2026.
  2. F2. The transaction was executed in multiple trades at prices ranging from $166.14 to $167.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. F3. The transaction was executed in multiple trades at prices ranging from $167.14 to $168.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. F4. The transaction was executed in multiple trades at prices ranging from $168.15 to $169.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. F5. The transaction was executed in multiple trades at prices ranging from $169.15 to $170.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  6. F6. The transaction was executed in multiple trades at prices ranging from $170.22 to $170.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  7. F7. Includes 65,613 restricted stock units.
  8. F8. Fully vested.
Options exercised 27,160 shares November 16, 2026
Exercise price $18.56 per share Options exercised November 16, 2026
Shares sold 27,160 shares Six transactions on November 16, 2026
Options remaining 108,640 options Following the November 16, 2026 exercise
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"the reported price reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RVMD shares did Stephen Michael Kelsey exercise and sell?

He exercised options for 27,160 shares and sold 27,160 shares on November 16, 2026. The exercise price was $18.56 per share; the six reported weighted-average sale prices were $166.7506, $167.6619, $168.6375, $169.4561, $170.3957 and $171.6500 per share.

Were Stephen Michael Kelsey's RVMD transactions made under a 10b5-1 plan?

Yes, they were made under a Rule 10b5-1 trading plan adopted August 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kelsey Stephen Michael

(Last)(First)(Middle)
REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE

(Street)
REDWOOD CITY CALIFORNIA 94063

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M(1)27,160A$18.56313,467D
Common Stock11/16/2026S(1)11,542D$166.7506(2)301,925D
Common Stock11/16/2026S(1)3,627D$167.6619(3)298,298D
Common Stock11/16/2026S(1)8,039D$168.6375(4)290,259D
Common Stock11/16/2026S(1)3,052D$169.4561(5)287,207D
Common Stock11/16/2026S(1)700D$170.3957(6)286,507D
Common Stock11/16/2026S(1)200D$171.65286,307(7)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$18.5611/16/2026M(1)27,160 (8)03/01/2032Common Stock27,160$0108,640D
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on August 17, 2026.
2. The transaction was executed in multiple trades at prices ranging from $166.14 to $167.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. The transaction was executed in multiple trades at prices ranging from $167.14 to $168.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
4. The transaction was executed in multiple trades at prices ranging from $168.15 to $169.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
5. The transaction was executed in multiple trades at prices ranging from $169.15 to $170.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
6. The transaction was executed in multiple trades at prices ranging from $170.22 to $170.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
7. Includes 65,613 restricted stock units.
8. Fully vested.
Remarks:
Senior Advisor to the Chief Executive Officer
/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading